Clinical Infectious Diseases Response to Reviewers: How to Write a Rebuttal That Wins (2026)
How to write a point-by-point response to reviewers for Clinical Infectious Diseases, where the clinical-significance and generalizability bar carries into the rebuttal and CID tells you not to lengthen the manuscript.
Readiness scan
Before you submit to Clinical Infectious Diseases, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Clinical Infectious Diseases at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 7.3 puts Clinical Infectious Diseases in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~25-35% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: Clinical Infectious Diseases takes ~~90-120 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Building a point-by-point response that is easy for reviewers and editors to trust. |
Start with | State the reviewer concern clearly, then pair each response with the exact evidence or revision. |
Common mistake | Sounding defensive or abstract instead of specific about what changed. |
Best next step | Turn the response into a visible checklist or matrix before you finalize the letter. |
Quick answer: A Clinical Infectious Diseases response to reviewers is a required point-by-point rebuttal that the associate editor reviews alongside your revised manuscript, with 60 days for a major revision and 30 days for a minor one. Open with a short letter to the handling editor, then answer each comment under Reviewer 1, Reviewer 2, and the editor, and specify the exact page and line number you cite for every change.
Two CID-specific rules drive everything: the clinical-significance and generalizability bar that earned the revision carries into the rebuttal, and CID explicitly tells you not to increase the manuscript's length while responding.
Start with the Clinical Infectious Diseases rebuttal readiness check before you submit, or work through this guide by hand. For broader cluster context, see the Clinical Infectious Diseases submission guide and the Clinical Infectious Diseases journal overview.
What does a Clinical Infectious Diseases response to reviewers require?
The Manusights Clinical Infectious Diseases rebuttal scan. This guide tells you what the associate editor and the two-plus reviewers look for in a CID rebuttal. The scan tells you whether YOUR response letter passes that check before you upload it to Editorial Manager submission portal. We have reviewed manuscripts and rebuttals targeting Clinical Infectious Diseases and peer IDSA journals; the patterns below are the same ones CID's clinician-editors and statistical editors flag at re-review. Sources are listed at the end. Your CID manuscript is never used to train any AI model and is deleted within 24 hours.
Three things make a Clinical Infectious Diseases rebuttal different from a generic one:
- CID is a clinical journal run by practicing infectious-disease clinicians. The bar that earned your revision is clinical consequence: does this change diagnosis, treatment, prevention, or antimicrobial stewardship? That bar carries straight into the rebuttal.
- CID imposes a hard revision clock and a do-not-lengthen rule. You get 60 days for a major revision, 30 for a minor one, plus an explicit instruction not to increase the manuscript's text length while responding.
- A statistical review from an in-house statistical editor may be required. Statistics comments then sit on a separate, harder track than the clinical reviewers' comments.
Use this guide to pressure-test your point-by-point response against all three before you submit.
How we built it (our methodology note): we reviewed CID's own General Instructions and author guidelines, checked the IDSA cross-journal pathway documentation, compared it to SciRev community reports, and matched it against our own pre-submission reviews of CID-targeted rebuttals. Every claim below traces to a primary source or our review corpus. CID accepts roughly 15 to 20 percent of submissions on third-party estimates, which is a sunk-cost reason to get the revision right the first time rather than risk a rejection on revision.
Element | What Clinical Infectious Diseases expects | What reviewers and editors flag at re-review |
|---|---|---|
Structure | Point-by-point response, editor letter then per-reviewer replies | Free-form prose answering all comments together |
New work | New analysis, subgroup, or sensitivity analysis for major revision | "We have clarified this in the text" with no new analysis |
Clinical claim | Implication matched exactly to what the data support | Overstated stewardship or practice-changing claim |
Length | Do not increase text length; stay inside the 3,500-word cap | Bolting new paragraphs on until the article-type cap breaks |
Specificity | Page and line number for every manuscript change | "We have updated the manuscript" with no location |
Statistics | Re-analysis with new estimates for statistical-editor comments | Prose answer to a statistical-review point |
Reporting | Completed CONSORT/STROBE/PRISMA checklist, registration number, data statement | A promised checklist instead of a completed one |
Source: Clinical Infectious Diseases General Instructions and author guidelines, Oxford Academic, accessed June 2026.
The copyable Clinical Infectious Diseases rebuttal template
The associate editor reads your rebuttal alongside the revised manuscript to decide whether the paper can now be accepted, so a clean, scannable structure is doing real work. Copy this skeleton, then replace the bracketed text with your own changes. Keep the reviewer text and your reply in two distinct fonts or colors.
Dear Editor,
Thank you for the opportunity to revise our manuscript the manuscript title (CID-[ID]). We are grateful to the reviewers and the editor for their careful comments. In response, we have added [new subgroup / sensitivity analysis], revised the clinical-significance framing in the Discussion, and completed the [CONSORT / STROBE] checklist. A point-by-point response follows; reviewer comments are in bold and our replies in plain text, with revised-manuscript page and line numbers given for every change.
Per the journal's guidance, we have not increased the overall manuscript length and remain within the 3,500-word Major Article limit.
----------------------------------------------------------------
Reviewer 1
Comment 1.1: "The single-center design limits generalizability of the
treatment effect."
Response: We agree. We have added a multivariable-adjusted analysis and
a sensitivity analysis restricted to [subgroup] (new Table 2), and we
have walked the clinical claim back to the population the data support.
Changed text appears on page 7, lines 18 to 24.
Comment 1.2: "The sample size for the primary endpoint is unclear."
Response: We have clarified that n = [N] per group and added the power
calculation to the Methods. See page 9, lines 3 to 9, and Supplementary
Table 3.
----------------------------------------------------------------
Reviewer 2
Comment 2.1: "The stewardship implication is overstated relative to the
effect size."
Response: We agree. We have revised the Conclusions to state the effect
size and 95% confidence interval and limited the stewardship claim to
[setting]. Revised text is on page 11, lines 5 to 12.
----------------------------------------------------------------
Editor / Statistical Review
Comment E.1: "Please provide the trial registration number and the
completed reporting checklist."
Response: The trial is registered (ClinicalTrials.gov [NCT number]); the
number now appears at the end of the Abstract. A completed CONSORT
checklist with page-and-line references is uploaded as Supplementary
material. See page 2 (Abstract) and the Data Availability statement on
page 16, lines 1 to 4.
We believe the revised manuscript now addresses each comment and we look
forward to your decision.
Sincerely,
[Corresponding author, on behalf of all authors]The template carries the four tokens that reviewers and editors actually scan for: a letter to the editor, a Reviewer 1 / Reviewer 2 / editor structure, explicit action language ("we have added", "we have revised", "we have clarified"), and a page and line reference for every change.
The page-and-line rule: cite the location of every change
State the exact page and line number for each manuscript revision, and reference the specific table, figure, or supplementary file you changed. This is the single most-cited rebuttal failure at Clinical Infectious Diseases. A CID associate editor who has to hunt for your subgroup analysis reads the silence as evasion; one who can click straight to page 7, lines 18 to 24, finishes faster and re-reviews more favorably.
Two CID-specific habits keep your locations reliable:
- Number against the revised file, not the original. Reviewers open the version you just uploaded to Editorial Manager submission portal, so line 18 has to mean line 18 there.
- Flag supplementary locations explicitly. CID's do-not-lengthen rule pushes much of your added detail into supplementary tables, so name the supplement ("new Supplementary Table 3") rather than letting the editor assume the change is in the main text.
Never write "we have addressed this in the manuscript" without a location.
Reviewer-text vs author-response typography
Make the reviewer's words and your reply visually distinct. Put each reviewer comment in bold or a colored text box, then keep your response in plain regular text directly beneath it. CID runs at least two reviewers per original-research paper, plus a third when more perspective is needed, and they all scan dozens of these letters; a layout where comment and reply blur together costs you the attention you need.
The distinction is not cosmetic at CID. The associate editor reads the point-by-point response against the revised manuscript to decide acceptability in one pass. A clean two-font or two-color layout is the difference between a document the editor can follow and one that triggers a second round just to clarify what you changed.
Tone calibration: how to phrase the hard replies
The reviewers and the editor see your tone across every comment. A defensive reply on a generalizability or statistics point is exactly where CID rebuttals stall. Calibrate.
Bad (defensive or vague) | Better (substantive and gracious) |
|---|---|
"The reviewer has misunderstood our design." | "We did not state the design clearly; we have rewritten the Methods on page 6 and added the inclusion and exclusion criteria explicitly." |
"Single-center data are sufficient here." | "We agree generalizability is a concern. We have added a multivariable-adjusted analysis and a sensitivity analysis (new Table 2, page 8) and limited the clinical claim to the population the data support." |
"We have addressed this concern." | "We have added the requested subgroup analysis (new Table 2, page 8, lines 2 to 8) and revised the Conclusions." |
"Our finding is clearly practice-changing." | "We have revised the Conclusions to report the effect size and 95% confidence interval and scoped the stewardship implication to [setting]; see page 11, lines 5 to 12." |
"The statistical request is outside our scope." | "We have run the requested analysis (Methods, page 9); the adjusted estimate is [value], and we have updated Table 2 and the Discussion accordingly." |
The pattern that works: concede where the reviewer is right, do the analysis, point to the exact change, scope every clinical claim to what the data support, and push back only on a request that is genuinely out of scope, with a reason and an alternative.
The Clinical Infectious Diseases reviewer culture you are writing into
Clinical Infectious Diseases is the flagship clinical journal of the Infectious Diseases Society of America, and its editors are practicing infectious-disease clinicians who triage on clinical consequence first. Three features of that culture shape every reply you write.
Who reads your rebuttal
External peer review is a single-anonymous process, with at least two independent reviewers for original research and a third added when more perspective is needed. On top of that, a statistical review from one of the journal's in-house statistical editors may be required, so a methods or analysis comment can sit on a separate, more demanding track than the clinical reviewers' comments.
SciRev community reports put CID's review rounds in the multi-week range. That sets your planning clock against the journal's hard return deadlines: 60 days for a major revision, 30 days for a minor one, counted from the revision request.
The clinical-significance and generalizability bar
The defining feature of a CID revision is the clinical-significance and generalizability bar. The editorial question that earned your revision is narrow: does this work change what a clinician does at the bedside, how a stewardship team prescribes, or how a health system manages infection?
That same question is applied again to your rebuttal. A response that fixes every methods point but leaves the clinical claim overstated, or that answers a generalizability concern with more single-center data, has not cleared the bar. The associate editor reviews both the revised manuscript and the point-by-point response and can accept, ask for another round, reject, or offer an IDSA transfer.
The do-not-lengthen rule
A second CID feature surprises authors: the journal explicitly says not to increase the manuscript's text length while responding, unless the decision letter says otherwise, and Major Articles are capped at 3,500 words. The standard rebuttal instinct, bolting new paragraphs onto the manuscript to satisfy each reviewer, works against you here. The discipline is to push added detail into the response letter and supplementary material, then tighten existing text to make room for any required addition.
Where CID sits in the field
How CID compares to its neighbors matters for calibration:
- New England Journal of Medicine / Lancet: a heavier novelty-and-practice bar, with an editorial process built around large trials.
- Open Forum Infectious Diseases: CID's IDSA open-access sister title, which sits on a soundness rather than clinical-priority bar.
- CID: in between. Clinically consequential ID research, a fast and priority-strict editorial culture, and a revision that has to hold the clinical claim.
Because the comments cluster on clinical significance, generalizability, and statistics, the rebuttal that wins is the one that does the analysis and scopes the claim, not the one that argues.
Key Insight
At CID the bar that earned your revision is clinical consequence, and it is applied again to your rebuttal. Answer a generalizability concern with the analysis that addresses external validity, and scope every clinical claim to exactly what the data support, before you upload the revision.
What our Clinical Infectious Diseases rebuttal reviews surface
In our pre-submission review work with Clinical Infectious Diseases submissions, the rebuttals that stall in a second revision round share a small set of recurring weaknesses. These are the same ones reviewers and editors flag at re-review. In our analysis of Clinical Infectious Diseases rebuttals, each weakness below maps to a specific, named failure pattern in the journal's editorial culture, and each is testable against your own draft response before you upload it.
Answering a generalizability concern with more single-center data. The most common and most expensive pattern in our Clinical Infectious Diseases pre-submission reviews is a rebuttal that meets a reviewer's external-validity concern by adding more retrospective cohort data from the same site.
CID editors triage on whether findings generalize to clinical practice, so more of the same data does not move the decision. The multivariable-adjusted analysis, the sensitivity analysis, or an honest scoping of the claim to the studied population does. Across our CID rebuttal reviews, this mismatch between the generalizability concern and the author's response is the single strongest predictor of a third round.
Overstating the clinical or stewardship implication. Because CID is a practice-facing journal, the editors read the Conclusions for claims the effect size and confidence interval do not support. In our Clinical Infectious Diseases pre-submission reviews we routinely find a rebuttal that defends a "practice-changing" or "stewardship" claim on a primary endpoint that was underpowered or measured in one setting. Walk the claim back to what the data show, report the estimate and its interval, and scope the implication to the population studied.
Incomplete reporting-checklist and statistics fixes. A rebuttal that promises a checklist instead of completing one, omits the trial-registration number, or answers an in-house statistical analysis comment with prose draws an immediate re-review note. In our pre-submission review work with Clinical Infectious Diseases manuscripts, responses that leave a CONSORT, STROBE, or PRISMA reference checklist with items pointing vaguely to "Methods," skip the RCT protocol, or leave the data availability statement half-finished consistently add a round.
The fix is concrete: complete the checklist with page-and-line references, put the registration number at the end of the Abstract, and answer statistical-editor comments with a re-analysis and new estimates.
Letting the revision break the word cap. Because CID tells authors not to increase the manuscript's length, a revision that bolts a new paragraph onto the results for every reviewer comment until the abstract and main text exceed the 3,500-word Major Article cap reads as undisciplined. In our Clinical Infectious Diseases pre-submission reviews, the rebuttals we flag here add net length the journal explicitly asked them not to add. Push detail into supplementary material and the response letter, and tighten existing text to make room.
Do the analysis, scope the claim, complete the reporting, and keep the length. That four-part discipline is what separates a Clinical Infectious Diseases rebuttal that clears one revision round from one that stalls into a second or third. Check whether your Clinical Infectious Diseases point-by-point response holds the clinical claim and the generalizability bar before you submit.
When to comply and when to push back
Situation | Recommended approach at Clinical Infectious Diseases |
|---|---|
Reviewer questions generalizability of single-center findings | Comply. Add a multivariable-adjusted or sensitivity analysis, or scope the claim to the studied population. |
Reviewer asks for an analysis genuinely outside the dataset | Push back with a reason, add the closest feasible analysis, and note the limitation in the Discussion. |
Reviewer or statistical editor flags the analysis | Comply. Re-run it, report the new estimate and interval, update the table. Do not answer with prose. |
Reviewer says the clinical or stewardship claim is overstated | Comply. Walk the claim back to what the effect size and interval support. |
Editor requests the reporting checklist or registration number | Comply. Complete the checklist with page references; put the registration number at the end of the Abstract. |
Reviewer asks for content that would break the word cap | Comply with the substance in supplementary material; do not lengthen the main manuscript. |
Source: Manusights pre-submission reviews of Clinical Infectious Diseases-targeted resubmissions, 2025 cohort.
Readiness check
Run the scan while Clinical Infectious Diseases's requirements are in front of you.
See how this manuscript scores against Clinical Infectious Diseases's requirements before you submit.
How much work a Clinical Infectious Diseases rebuttal actually takes
Authors consistently underestimate the new-analysis effort and overestimate the writing effort. This breakdown is about workload, not the journal's decision clock; for the end-to-end decision schedule, see the Clinical Infectious Diseases review time guide.
Rebuttal task | Where the effort goes | What it costs you |
|---|---|---|
Reading and clustering reviewer reports | Finding the one clinical-significance concern behind the comments | A day of careful reading, not a skim |
Running new analyses or subgroups | The actual bar for a CID major revision | The bulk of the work, often two to four weeks |
Completing the reporting checklist and registration | CONSORT/STROBE/PRISMA, trial registration, data statement | A focused half-day, not a promise |
Writing the point-by-point replies | One reply plus a page and line reference per comment | Less than authors fear once the analyses exist |
Keeping inside the word cap | Tightening text and moving detail to supplementary | Skipped most often, and the editor notices |
Source: Manusights pre-submission reviews of Clinical Infectious Diseases resubmissions, 2025 cohort, last updated June 7, 2026.
Budget the analysis, not the prose
The new analyses, not the writing, are what consume a CID major revision. With 60 days from the revision request, plan the re-analysis and any added subgroup first, then write the point-by-point replies around results you already have.
Honest friction: rejection on revision is real
A major-revision invitation at Clinical Infectious Diseases is not a soft acceptance. The associate editor reviews both the revised manuscript and your point-by-point response, and the paper can still end in rejection after re-review if the new work does not clear the clinical-significance bar, or it can be offered a transfer to another IDSA journal. CID accepts only about 15 to 20 percent of submissions on third-party estimates, so the revision stage stays genuinely competitive.
Most rejections at this stage trace to one cause: the author answered a generalizability or clinical-significance concern with more description instead of the analysis that addresses it. The second most common is an overstated clinical or stewardship claim the data do not support.
Think twice before you resubmit if any of these are true:
- The response uses generic "we have addressed this" language with no page or line numbers.
- A reviewer questioned generalizability and you answered with more single-center data.
- The Conclusions still claim a practice-changing effect the confidence interval does not support.
- The reporting checklist is promised rather than completed, or the trial-registration number is missing.
- The revision quietly increased the manuscript length the journal asked you not to increase.
Fixing these before resubmission is what keeps a major revision from becoming a rejection on revision.
The IDSA transfer pathway: where your rebuttal travels next
If CID rejects the paper or decides it is a better fit elsewhere, the editors may offer a transfer within the IDSA family, most often to Open Forum Infectious Diseases (the IDSA open-access sister title) or the Journal of Infectious Diseases.
Under the IDSA pathway for previously reviewed papers, you carry the CID review forward by uploading:
- the CID decision letter with the reviewer comments in full,
- your point-by-point response as supplementary material, and
- a track-changes plus clean version of the manuscript.
If the receiving editors agree the prior comments were fully addressed, they may accept without additional external review; otherwise they may send it for further review. The practical consequence: the CID rebuttal you write is not throwaway, because it can become the exact document the next IDSA journal evaluates. For the full ladder of where to go next, see rejected from Clinical Infectious Diseases.
Red flags a Clinical Infectious Diseases reviewer spots in seconds
Before you upload, scan your own rebuttal for the patterns that draw an immediate re-review comment. Each is a specific, checkable thing in your draft, not a vague quality dimension.
- A reply with no location. Any "we have revised the manuscript" with no page and line number reads as evasion the moment a reviewer cannot find the change.
- More of the same data for a generalizability concern. A reviewer questioned external validity and the reply adds another single-center cohort instead of the analysis or the scoped claim.
This is the single most common cause of a third round.
- An overstated clinical claim. A "practice-changing" or "stewardship" conclusion the effect size and confidence interval do not support, in a journal whose editors are practicing clinicians.
- A promised checklist. A CONSORT/STROBE/PRISMA checklist described but not completed, or a missing trial-registration number, when CID enforces these at the file level.
How does this guide go beyond the Clinical Infectious Diseases author guidelines?
The official guidelines tell you to submit a point-by-point response, return a major revision within 60 days, and not increase the manuscript length. What they do not tell you is the part that changes how you write every reply:
- the clinical-significance and generalizability bar that earned the revision is applied again to your rebuttal;
- a generalizability concern needs the analysis, not more single-center data;
- an in-house statistical editor can put your statistics on a separate, harder track;
- the rebuttal can travel to OFID or JID under the IDSA pathway, so it is not throwaway.
The patterns above come from our pre-submission reviews of Clinical Infectious Diseases rebuttals. They are testable against your own draft today, not theoretical concerns.
- Manusights pre-submission reviews of Clinical Infectious Diseases-targeted manuscripts (2025 cohort)
Frequently asked questions
Open with a short letter to the handling editor summarizing the major changes, then list each comment in order under Reviewer 1, Reviewer 2, and the editor, quote the reviewer text in full, state the exact change you made, and give the page and line number in the revised manuscript. CID requires a point-by-point response so the editors can evaluate the revision and understand your thinking behind any changes you did not make.
CID gives you 60 days to return a major revision and 30 days to return a minor revision, counted from the date of the revision request. The clock is real: budget the new analysis time inside that window, because most of the work in an infectious-disease rebuttal is the re-analysis or added subgroup, not the writing.
CID is a clinical journal, so revisions usually mean new analyses, added subgroups, a sensitivity analysis, or stronger outcome documentation rather than bench experiments. The bar is clinical significance and generalizability: if a reviewer questions whether single-center findings generalize, the answer is the analysis that addresses external validity, not more data from the same site. A statistical review from an in-house statistical editor may also be required, so statistics comments need a re-analysis with new estimates, not prose.
Yes. A major-revision invitation is not an acceptance. When you return the revision, the associate editor reviews both the revised manuscript and your point-by-point response, and may accept, ask for a second round of review or revision, reject, or offer a transfer to another IDSA journal such as Open Forum Infectious Diseases. The most common reason a revision fails is overstating the clinical or stewardship implication on evidence the data do not support.
No. CID states that unless the decision letter says otherwise, you should not increase the text length of the manuscript while responding to comments. Major Articles are capped at 3,500 words. Put the detail in the response letter and the supplementary material, tighten existing text to make room for any required addition, and keep the main manuscript inside its article-type limit.
Sources
- General Instructions, Clinical Infectious Diseases, Oxford Academic (accessed June 2026)
- Author guidelines, Clinical Infectious Diseases, Oxford Academic (accessed June 2026)
- Pathway for previously reviewed papers, IDSA Journals, Oxford Academic (accessed June 2026)
- Clinical Infectious Diseases, Infectious Diseases Society of America (accessed June 2026)
- Ten simple rules for writing a response to reviewers, William Stafford Noble, PLOS Computational Biology (accessed June 2026)
- On the art of the rebuttal, Nature Computational Science (2025) (accessed June 2026)
- Reviews for Clinical Infectious Diseases, SciRev (accessed June 2026)
Final step
Submitting to Clinical Infectious Diseases?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Clinical Infectious Diseases
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
- Clinical Infectious Diseases Submission Guide: Scope, Format & Tips
- How to Avoid Desk Rejection at Clinical Infectious Diseases
- Clinical Infectious Diseases Review Time: What Authors Can Actually Expect
- Rejected from Clinical Infectious Diseases? The 7 Best Journals to Submit Next
- Clinical Infectious Diseases Formatting Requirements: Complete Author Guide
- Clinical Infectious Diseases 'Under Review': What Each Status Means and When to Expect a Decision
Supporting reads
Conversion step
Submitting to Clinical Infectious Diseases?
Anthropic Privacy Partner. Zero-retention manuscript processing.